Venus Remedies completes clinical trials for cephalosporin for pneumonia

By Lisa Kerner

Erie, Pa., April 10 - Venus Remedies Ltd said it has successfully completed the phase 3 clinical trials for its new formulation, fixed-dose combination drug of the latest generation cephalosporin with an amino-glycoside.

The drug is designed to treat both hospital acquired pneumonia and community acquired pneumonia, and febrile neutropenia, according to a company news release.

Venus said results of clinical trials have proved that the new formulation is 25 times more effective than the fourth-generation cephalosporin. In addition, the treatment span has been reduced by about 50% resulting is shorter hospital stays and a cost savings for patients.

The company has filed a patent application with the Indian Patent Office for the formulation, as well as an international patent application.

Venus is a Haryana, India-based pharmaceutical manufacturing plant.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.